Cargando…

PPARs and Mitochondrial Metabolism: From NAFLD to HCC

Metabolic related diseases, such as type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD), are widespread threats which bring about a significant burden of deaths worldwide, mainly due to cardiovascular events and cancer. The pathogenesis of these diseases is extremely co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mello, Tommaso, Materozzi, Maria, Galli, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223052/ https://www.ncbi.nlm.nih.gov/pubmed/28115925 http://dx.doi.org/10.1155/2016/7403230

Ejemplares similares

Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
por: Campani, Claudia, et al.
Publicado: (2020)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

NAFLD-Associated HCC: Progress and Opportunities
por: Geh, Daniel, et al.
Publicado: (2021)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
por: Song, Qian, et al.
Publicado: (2022)

NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models
por: Fang, Jing, et al.
Publicado: (2023)

Insights into the Role of PPARβ/δ in NAFLD
por: Chen, Jiapeng, et al.
Publicado: (2018)

Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion
por: Zhang, Chunye, et al.
Publicado: (2021)

The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
por: Dixon, Emmanuel D., et al.
Publicado: (2021)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?
por: Eldafashi, Nardeen, et al.
Publicado: (2021)

NAFLD and MAFLD as emerging causes of HCC: A populational study
por: Myers, Shuna, et al.
Publicado: (2021)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

NAFLD as a risk factor for HCC: new rules of engagement?
por: Masuzaki, Ryota, et al.
Publicado: (2016)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC
por: Rusu, Ioana, et al.
Publicado: (2022)

Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs
por: Mukherjee, Anirban Goutam, et al.
Publicado: (2022)

Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring
por: Mello, Tommaso, et al.
Publicado: (2019)

PPARs modulate cardiac metabolism and mitochondrial function in diabetes
por: Lee, Ting-Wei, et al.
Publicado: (2017)

The Role of Stem Cell Factor, Epidermal Growth Factor and Angiopoietin-2 in HBV, HCV, HCC and NAFLD
por: Radmanić, Leona, et al.
Publicado: (2022)

ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy
por: Tian, Yuan, et al.
Publicado: (2019)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?
por: Theys, Claudia, et al.
Publicado: (2022)

Mitochondrial oxidative function in NAFLD: Friend or foe?
por: Shum, Michael, et al.
Publicado: (2020)

Comorbidities and Metabolic Derangement of NAFLD
por: Bang, Ki Bae, et al.
Publicado: (2015)

Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity
por: Régnier, Marion, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?
por: MUNTEANU, MIHAI ALEXANDRU, et al.
Publicado: (2014)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

The Link between NAFLD and Metabolic Syndrome
por: Radu, Fabiana, et al.
Publicado: (2023)

Environmental Pollution: A Tangible Risk for NAFLD Pathogenesis
por: Arciello, Mario, et al.
Publicado: (2013)

Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD
por: Sinha, Rohit Anthony, et al.
Publicado: (2016)

Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk
por: Dabravolski, Siarhei A., et al.
Publicado: (2021)

NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
por: Godoy-Matos, Amélio F., et al.
Publicado: (2020)

PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
por: Wang, Yaping, et al.
Publicado: (2020)

The Potential Use of Metabolic Cofactors in Treatment of NAFLD
por: Mardinoglu, Adil, et al.
Publicado: (2019)

Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
por: Jegatheesan, Prasanthi, et al.
Publicado: (2017)

The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD
por: Östlund, Cecilia, et al.
Publicado: (2020)

Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD
por: An, Lingxuan, et al.
Publicado: (2023)

Gut Microbiota: Association with NAFLD and Metabolic Disturbances
por: Lau, E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6uj55k2suu0pg27aq9id2qjrrv